Literature DB >> 12527890

Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA.

Jingxia Li1, Cuiling Ma, Yi Huang, Jia Luo, Chuanshu Huang.   

Abstract

The transcription factor activator protein-1 (AP-1) has been implicated in a large variety of biological processes including cell differentiation, proliferation, apoptosis and oncogenic transformation. It is thought that the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced AP-1 activity is because of the activation of the PKC/MAPK/AP-1 pathway, although the detailed molecular mechanism has not been fully characterized. The tyrosine kinases of epidermal growth factor receptor (EGFR) lie at the head of a complex of signal transduction cascade that modulates cell proliferation, survival, adhesion, migration and differentiation. Currently, little is known about whether EGFR or its tyrosine kinase is necessary for TPA-induced AP-1 activation. In the present study, we investigated this issue using a well-characterized mouse fibroblast B82 cell line, which is devoid of the EGFR, and its stable transfectants with either wild-type EGFR (B82L) or tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721). We demonstrated that the TPA or epidermal growth factor (EGF) induced AP-1 activation in the B82L cells that express wild-type EGFR, but not in the B82 cell, whereas autophosphorylation at tyrosine(1173) of EGFR in B82L cells was only induced by EGF, but not TPA. The expression of tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721) resulted in deficiency of AP-1 induction in cellular response to EGF, while TPA treatment led to fully AP-1 activation. Furthermore, the mutation at Lys-721 of EGFR resulted in impairing of EGFR autophosphorylation at tyrosine(1173) induced by EGF. Based on these results, we conclude that TPA-induced AP-1 activation requires the basal level-EGFR protein, but not EGFR tyrosine kinase and EGFR autophosphorylation at tyrosine(1173), whereas both EGFR tyrosine kinase and EGFR autophosphorylation at Y(1173) play a critical role in EGF-induced AP-1 activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527890     DOI: 10.1038/sj.onc.1206102

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  NFAT3 is required for EGF-induced COX-2 transcription, but neither iNOS transcription nor cell transformation in Cl 41 cells.

Authors:  Jingxia Li; Haitian Lu; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

2.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.

Authors:  Masahiro Seike; Akiteru Goto; Tetsuya Okano; Elise D Bowman; Aaron J Schetter; Izumi Horikawa; Ewy A Mathe; Jin Jen; Ping Yang; Haruhiko Sugimura; Akihiko Gemma; Shoji Kudoh; Carlo M Croce; Curtis C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-13       Impact factor: 11.205

3.  Blockade of Ets-1 attenuates epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells.

Authors:  Velidi H Rao; Vikrant Rai; Samantha Stoupa; Devendra K Agrawal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-07       Impact factor: 4.733

4.  Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line.

Authors:  Woo-Sik Jeong; In-Wha Kim; Rong Hu; Ah-Ng Tony Kong
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

5.  Methamphetamine signals transcription of IL1β and TNFα in a reactive oxygen species-dependent manner and interacts with HIV-1 Tat to decrease antioxidant defense mechanisms.

Authors:  Liana V Basova; Whitney Vien; Nikki Bortell; Julia A Najera; Maria Cecilia Garibaldi Marcondes
Journal:  Front Cell Neurosci       Date:  2022-08-18       Impact factor: 6.147

6.  Disruption of pathways regulated by Integrator complex in Galloway-Mowat syndrome due to WDR73 mutations.

Authors:  F C Tilley; C Arrondel; C Chhuon; M Boisson; N Cagnard; M Parisot; G Menara; N Lefort; I C Guerrera; C Bole-Feysot; A Benmerah; C Antignac; G Mollet
Journal:  Sci Rep       Date:  2021-03-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.